Sharekhan has given Buy recommendation for Gland Pharma with a target price of Rs. 4400 in its research report issued on Nov 26, 2021

Sharekhan’s research report on Gland Pharma

Gland plans to increase the share of revenues from RoW markets to 40% (21% Currently) over next 3-4 yea led by a strong growth from foray in China markets and increasing penetration in existing Row markets. Well dive ified product portfolio, strong product pipeline and strengthening of the base business in the US would drive the Core market segment performance. Vaccine manufacturing opportunity has taken Gland closer to its long term strategy of entering the lucrative biosimilar CDMO space.

Outlook

We re-iterate Buy recommendation on Gland Pharma (Gland) with an unchanged PT of 4,400

Leave a Reply

Your email address will not be published.